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Folic Acid Improves Endothelial Function in Coronary
Artery Disease via Mechanisms Largely Independent
of Homocysteine Lowering
Sagar N. Doshi, BSc, MBChB, MRCP; Ian F.W. McDowell, MD, MRCP, FRCPath;
Stuart J. Moat, BSc, PhD; Nicola Payne, BSc; Hilary J. Durrant, PhD, MBChB, MRCP;
Malcolm J. Lewis, PhD, DSc, FESC; Jonathan Goodfellow, BSc, MBBS, MRCP
Background—Homocysteine is a risk factor for coronary artery disease (CAD), although a causal relation remains to be
proven. The importance of determining direct causality rests in the fact that plasma homocysteine can be safely and
inexpensively reduced by 25% with folic acid. This reduction is maximally achieved by doses of 0.4 mg/d. High-dose
folic acid (5 mg/d) improves endothelial function in CAD, although the mechanism is controversial. It has been proposed
that improvement occurs through reduction in total (tHcy) or free (non–protein bound) homocysteine (fHcy). We
investigated the effects of folic acid on endothelial function before a change in homocysteine in patients with CAD.
Methods and Results—A randomized, placebo-controlled study of folic acid (5 mg/d) for 6 weeks was undertaken in 33
patients. Endothelial function, assessed by flow-mediated dilatation (FMD), was measured before, at 2 and 4 hours after
the first dose of folic acid, and after 6 weeks of treatment. Plasma folate increased markedly by 1 hour (200 compared
with 25.8 nmol/L; P0.001). FMD improved at 2 hours (83 compared with 47 m; P0.001) and was largely complete
by 4 hours (101 compared with 51 m; P0.001). tHcy did not significantly differ acutely (4-hour tHcy, 9.56 compared
with 9.79 mol/L; PNS). fHcy did not differ at 3 hours but was slightly reduced at 4 hours (1.55 compared with 1.78
mol/L; P0.02). FMD improvement did not correlate with reductions in either fHcy or tHcy at any time.
Conclusions—These data suggest that folic acid improves endothelial function in CAD acutely by a mechanism largely
independent of homocysteine. (Circulation. 2002;105:22-26.)
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Elevated total plasma homocysteine (tHcy) is now anaccepted and potentially modifiable risk factor for car-
diovascular disease and death that appears to be largely
independent of other conventional risk factors.1,2 However, it
remains controversial as to whether the increased risk is
mediated directly by homocysteine or whether homocysteine
may simply be an epiphenomenon.3
Plasma homocysteine can be safely and inexpensively
reduced by supplementation with oral B-group vitamins.
Folic acid reduces total plasma homocysteine by 25%4 and is
maximally achieved by doses of 0.4 to 0.5 mg daily.4,5 This
has led to the proposal that folic acid treatment may reduce
cardiovascular risk by reducing tHcy.
Endothelial dysfunction is a key process in atherosclerosis6
and independently predicts cardiovascular events.7 High-dose
folic acid (5 mg daily), alone or in combination with other
B-group vitamins, can improve endothelial function in pa-
tients with coronary artery disease (CAD). However, the data
are limited, and whether this improvement is due to a
reduction in homocysteine or some other effect of folic acid
is uncertain.8–10
We sought to investigate whether high-dose folic acid
supplementation would improve endothelial dysfunction in
patients with significant CAD who were taking standard
therapy, independent of changes in homocysteine.
Methods
Study Design
The study was a randomized, double-blind, placebo-controlled,
parallel design in which 33 patients were allocated to receive either
5 mg daily folic acid (16 patients) or matched placebo (17 patients)
for 6 weeks. Patients attended on 2 occasions separated by 6 weeks.
All patients gave written informed consent, and the protocol con-
formed to the Declaration of Helsinki.
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Subjects
Patients with CAD who were 70 years of age were recruited. We
defined CAD as either angiographically proven coronary disease
(50% luminal stenosis) or a history of myocardial infarction
(creatinine kinase rise2-fold normal with ECG changes). The level
of plasma homocysteine was not an entry criterion. Patients were
excluded if an acute coronary event had occurred 3 months before
entry or if there was diabetes mellitus, uncontrolled hypertension,
fasting plasma cholesterol 6.5 mmol/L, impaired renal function
(creatinine 120 mol/L), or clinically significant heart failure.
Patients actively smoking or who had recently ceased smoking (6
months), patients taking antioxidant vitamins (E or C), folic acid, or
fish oils, and women taking hormone replacement were also ex-
cluded. All selected subjects were tested to exclude vitamin B12
deficiency before entry, which precludes folic acid treatment.
Study Protocol
Biochemical Parameters
Lipids, glucose, creatinine, and B12 were analyzed on the day of
sampling; other samples were separated and the serum/plasma stored at
70°C until analysis. EDTA plasma for fHcy (non–protein bound)
assay was deproteinized within 15 minutes of venepuncture before
storage. EDTA plasma for tHcy assay was immediately separated by
centrifuging before storage. At the first visit, venous blood was drawn
before and at each hour for 4 hours after the first tablet for assay of
plasma folate, fHcy, and tHcy. 5-Methyltetrahydrofolate (5-MTHF) was
assayed in the folate group at baseline, 1 to 4 hours, and 6 weeks.
Subjects were recumbent on a couch during the 4 hours after the first
dose.
Noninvasive Measurement of Endothelial Function
Endothelial vasomotor function was assessed by flow-mediated
dilatation (FMD), a nitric oxide–mediated process.11,12 FMD was
measured by means of high-resolution ultrasound and wall-tracking,
as previously described by us, after release of a cuff placed at the
wrist, inflated for 5 minutes at 250 mm Hg.13,14 FMD was taken as
the greatest absolute increase in vessel end-diastolic diameter (EDD)
during the first 3 minutes after cuff release. Vascular studies were
performed by a single experienced operator in a temperature-
controlled room (21° to 24°C) at the same time of day on patients
fasted overnight. Medications were omitted on the morning of the
visit, and nitrates were withheld for 24 hours before studies.
Endothelium-independent dilation, in response to 400 g glyceryl
trinitrate, was recorded at baseline, 4 hours, and 6 weeks. Blood
pressure was measured continuously in the study arm by means of
photophlethysmography (Finapres). Blood flow was calculated as
the product of the Doppler time-velocity integral, heart rate, and
brachial artery diameter measured by wall-tracking at that time.
FMD was recorded before, at 2 and 4 hours after the first dose, and
after 6 weeks of daily treatment.
Biochemical Assays
Lipids, glucose, and creatinine were assayed routinely. tHcy was
measured by enzymatic immunoassay (Abbot IMx, Abbot Diagnos-
tics) and B12 was measured by competitive protein binding assays on
an Elecys 2010 analyzer (Roche Diagnostics). Folate was measured
by competitive binding assay with an IMx analyzer (Abbot Diag-
nostics). fHcy was measured by HPLC with fluorescence detection,
with a modification of the technique described by Araki and Sako.15
5-MTHF was measured by HPLC.16
Withdrawals, Medication Changes,
and Compliance
All randomized patients completed the study. Other medications
remained unchanged during the study period. No side effects were
reported, and compliance assessed by a tablet count was 98%.
Statistical Analysis
Results are expressed as meanSD unless otherwise stated. The
main statistical analysis of the folic acid study was analyzed by
ANCOVA. The associations between changes in FMD and tHcy,
fHcy, plasma folate, and 5-MTHF were assessed by Spearman rank
correlation analysis. A value of P0.05 was considered statistically
significant. We calculated that 18 subjects would be required to
detect an improvement in FMD from 40 m (SD, 20 m) to 80 m
(SD, 30 m) in the intervention group, with 90% power at the 5%
significance level.
Results
Baseline Characteristics
The study comprised 33 patients (30 men and 3 women).
There were no significant differences in baseline clinical or
biochemical parameters (Tables 1 and 2).
Effects on FMD and Vascular Measurements
FMD was impaired in both groups at baseline compared with
published normal values (folic acid, 1.260.75% EDD;
placebo, 1.140.62% EDD) (Table 3).17 After folic acid,
FMD improved markedly at 2 and 4 hours after the first dose
(Figure 1), with small additional improvement after 6 weeks
of daily treatment compared with the change at 4 hours
(FMD, 111 compared with 101 m; P0.04). There was no
significant difference between the glyceryl trinitrate response
TABLE 1. Clinical Characteristics of Study Subjects
Characteristic
Placebo
(n17)
Folate
(n16) P
Age 567 557 NS
Male:female 16/1 14/2 NS
Height, m 1.730.05 1.710.07 NS
Weight, kg 81.212 89.913 NS
Angiographic CAD 16 (94.1) 16 (100) NS
Myocardial infarction 10 (58.8) 9 (56.3) NS
Revascularization (CABG or
PTCA)
15 (88.3) 13 (81.3) NS
Hypertension 7 (41.2) 5 (31.3) NS
Family history 60 y 11 (64.7) 9 (56.3) NS
Smoking history 13 (81.3) 10 (58.8) NS
Cerebrovascular event 1 (5.9) 0 (0) NS
Peripheral vascular disease 1 (5.9) 1 (6.3) NS
Angina 2 (11.8) 2 (12.5) NS
Antiplatelet therapy 15 (88.3) 16 (100) NS
Lipid-lowering therapy 16 (94.1) 16 (100) NS
Statin 14 (82.4) 14 (87.5) NS
Fibrate 3 (17.6) 3 (18.8) NS
Other drug therapy
-Blocker 10 (58.8) 6 (37.5) NS
ACE inhibitor 1 (5.9) 1 (6.3) NS
Calcium channel blocker 2 (11.8) 3 (18.8) NS
ATII receptor blocker 0 (0) 1 (6.3) NS
Nitrate 2 (11.8) 1 (6.3) NS
ATII receptor blocker indicates angiotensin II receptor antagonist.
Data are presented as meanSD or patient numbers and percentages in
parentheses.
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at baseline and at 4 hours and 6 weeks. Heart rate, blood
pressure, brachial artery EDD, and baseline and peak hyper-
emic flow did not differ significantly after folic acid.
Effects on Biochemical Parameters
Plasma folate in the treatment group increased markedly by 1
hour and remained elevated at 2, 3, and 4 hours and at 6
weeks (Figure 2). tHcy fell in both groups during the initial 4
hours. There were no significant differences between tHcy
levels during the 4 hours after the first dose of folic acid, but
tHcy was significantly decreased after 6 weeks of treatment
(Figure 3). fHcy (non–protein bound) fell in both groups but
was not significantly altered during the first 3 hours after folic
acid. fHcy was significantly reduced at 4 hours and 6 weeks
(Figure 4). 5-MTHF increased from a baseline of 22.1 to
132.1 at 4 hours and 305.7 nmol/L at 6 weeks in the folate
group (Figure 5). Vitamin B12, HDL, LDL, triglycerides,
glucose, and creatinine were unchanged by folic acid after 6
weeks. Cholesterol was marginally higher in the folic acid
group and lower in the placebo group at 6 weeks (Table 2).
Correlates of Improved FMD
In univariate analysis, the change in FMD did not correlate
with either tHcy or fHcy reduction or with folate or 5-MTHF
increase at any point of the intervention (2 or 4 hours or 6
weeks; PNS).
Discussion
The present study confirms and extends the findings of recent
studies demonstrating improved endothelial function in pa-
tients with CAD taking high-dose folic acid (5 mg daily for
1.5 to 4 months) alone or in combination with other B-group
vitamins.8–10
The mechanism underlying this improvement is controver-
sial and has been previously attributed to reductions in either
tHcy or fHcy that occur with folate therapy.8,9 The present
TABLE 2. Biochemical Parameters at Baseline and 6 Weeks
Variable
Baseline 6 wk
Placebo
(n17)
Folate
(n16) P *
Placebo
(n17)
Folate
(n16) P†
Plasma folate, nmol/L 26.096.8 22.378.7 NS 26.85.6 604.22429 0.001
Total homocysteine, mol/L 10.82.2 10.62.6 NS 10.82.1 8.31.3 0.001
Free homocysteine, mol/L 1.990.47 2.050.49 NS 1.840.38 1.460.34 0.001
Vitamin B12, pmol/L 312105 30673 NS 32697 32781 NS
Cholesterol, mmol/L 4.470.57 4.360.87 NS 4.30.58 4.620.84 0.01
HDL cholesterol, mmol/L 1.160.36 1.080.2 NS 1.160.42 1.090.23 NS
LDL cholesterol, mmol/L 2.650.48 2.70.77 NS 2.410.47 2.740.83 NS
Triglycerides, mmol/L 1.450.7 1.430.45 NS 1.691.21 1.730.84 NS
Glucose, mmol/L 5.490.75 5.60.77 NS 5.520.72 5.610.93 NS
Creatinine, mol/L 95.112.1 98.718.1 NS 92.811.4 95.214.5 NS
Data are presented as meanSD. Comparing changes on folic acid with changes on placebo at baseline* and after
6 weeks of treatment.†
TABLE 3. Vascular Data at Baseline, 2 and 4 hours After the First Dose of Folic Acid and Placebo, and After 6 Weeks of
Daily Treatment
Variable
Baseline
Folate
(n16)
Baseline
Placebo
(n17) P *
2-h
Folate
(n16)
2-h
Placebo
(n17) P †
4-h
Folate
(n16)
4-h
Placebo
(n17) P ‡
6-wk
Folate
(n16)
6-wk
Placebo
(n17) P §
Vessel EDD, mm 4.290.7 4.200.5 NS 4.290.7 4.210.5 NS 4.290.6 4.190.5 NS 4.270.7 4.180.5 NS
FMD, m 52.529 4824 NS 8333 4723 0.001 10035 5120 0.001 11128 5219 0.001
GTN diameter
change, m
41552 39663 NS 41962 40953 NS 43137 40260 NS
Baseline blood flow,
mL/min
3515 3718 NS 355 3514 NS 3411 3312 NS 3413 3312 NS
Peak hyperemic
flow, mL/min
18067 18954 NS 18460 19254 NS 18649 19155 NS 18652 18955 NS
Heart rate, bpm 588 6111 NS 588 6010 NS 598 6211 NS 598 6212 NS
Systolic blood
pressure, mm Hg
13318 13115 NS 13318 12914 NS 13318 13115 NS 13319 13013 NS
Diastolic blood
pressure, mm Hg
716 7510 NS 727 7410 NS 717 749 NS 709 729 NS
GTN indicates glyceryl trinitrate.
Data are presented as meanSD. Comparing changes on folic acid with changes on placebo at baseline,* 2 hours,† 4 hours,‡ and 6 weeks.§
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study, however, provides new evidence indicating that homo-
cysteine reduction is unlikely to account for the acute and
possibly the chronic improvement observed with folic acid.
Improvement in endothelial function was observed acutely
after the first oral dose of folic acid and before any significant
reduction in tHcy. tHcy fell in both groups in the acute phase,
an effect that has been previously noted and due to reduction
in plasma albumin induced by supine posture.18 Interestingly,
despite a large fall in tHcy in the placebo group (9.83.9% at
4 hours), no change in endothelial function was observed.
This observation strengthens the conclusion that improved
endothelial function in the folate group was not mediated by
the similar reduction in tHcy in the acute phase. Furthermore,
no correlation was found between FMD improvement and
tHcy reduction at any time point. At 6 weeks, tHcy was
significantly reduced by folic acid, with only a small further
improvement in FMD compared with the effect at 4 hours
(111 compared with 101 m; P0.042). This finding is
consistent with some additional improvement conferred by
tHcy reduction at 6 weeks but may be explained by enhance-
ment after long-term folic acid treatment.
Improvement in FMD also occurred before a significant
fall in fHcy, indicating that enhancement was also not
explained by reduction in fHcy. Furthermore, no correlation
was found between improvement in FMD and reduction in
fHcy at any time.
Levels of plasma folate were increased to supraphysiolog-
ical levels (45.3 nmol/L) by 1 hour and remained elevated
thereafter. Under normal conditions, the majority (80%) of
circulating folate exists as the metabolically active form,
5-MTHF. Plasma 5-MTHF is increased acutely after folic
acid loading.19 Levels were supraphysiological by 1 hour
after folic acid and were further increased at 6 weeks
compared with the 4-hour level. The mechanism behind this
increase is unclear but in part may be explained by induction
of dihydrofolate reductase, the enzyme responsible for the
initial step in the conversion of folic acid to 5-MTHF. Such
induction has been observed with methotrexate in vitro after
48 hours.20 Whatever the mechanism, the increased level of
5-MTHF at 6 weeks may account for the further improvement
in endothelial function observed at 6 weeks.
It is likely that the majority of improvement in endothelial
function observed in the present study is due to direct
pharmacological actions of folic acid rather than reductions in
tHcy or fHcy. It is important to stress that plasma folate levels
observed in this study cannot be achieved by dietary fortifi-
cation with folic acid (up to 0.665 mg/d)21 or low-dose (0.4
mg) folic acid supplementation.5 Plausible mechanisms exist
Figure 2. Time course of plasma folate after first dose of pla-
cebo or folic acid (5 mg) and after 6 weeks of treatment
(meanSEM). Plasma folate was increased to supraphysiologi-
cal levels at 1 hour and remained so at all subsequent times.
*P0.001, comparing change on folic acid with change on
placebo.
Figure 4. Time course of fHcy after first dose of placebo or folic
acid (5 mg) and after 6 weeks of treatment (meanSEM). fHcy
fell in both groups due to a recumbent posture but did not sig-
nificantly differ for the initial 3 hours. fHcy was significantly
lower at 4 hours and 6 weeks after folic acid.
Figure 1. FMD before, at 2 and 4 hours after first dose, and
after 6 weeks of folic acid (5 mg daily) or placebo. Data are pre-
sented as meanSEM. FMD was defined as the greatest (abso-
lute) increase in EDD during the first 3 minutes after cuff release.
*P0.001, comparing change on folic acid with change on
placebo.
Figure 3. Time course of tHcy after first dose of placebo or folic
acid (5 mg) and after 6 weeks of treatment (meanSEM). tHcy
fell in both groups due to recumbent posture but did not signifi-
cantly differ for initial 4 hours. By 6 weeks tHcy was significantly
lower in the folic acid group. P0.001, comparing change on
folic acid with change on placebo.
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to explain how folic acid may acutely enhance endothelial
function independent of homocysteine. In vitro, 5-MTHF has
intrinsic antioxidant actions, can increase nitric oxide produc-
tion by endothelial nitric oxide synthase, and, furthermore,
can reduce superoxide production by endothelial nitric oxide
synthase in the setting of reduced cofactor tetrahydrobiop-
terin (BH4) bioavailability.22,23 In vivo, the intra-arterial
infusion of 5-MTHF will acutely improve endothelial func-
tion in familial hypercholesterolemia23 and CAD10 without
lowering homocysteine. Similarly, the effects of methionine
loading (100 mg/kg), which increases plasma homocysteine
and acutely impairs endothelial function,24 is abrogated by
simultaneous administration of folic acid (20 mg) without
alteration of homocysteine increase.25
Implications of the Study
These data show that improved endothelial function observed
with high-dose folic acid in CAD occurs acutely and is
independent of changes in either tHcy or fHcy. It seems
probable that this occurs largely by direct mechanisms other
than through homocysteine reduction. The homocysteine-
reducing effect of folic acid in CAD is maximal at 0.4 mg in
patients with normal renal function.5 However, if homocys-
teine lowering is not the major mechanism of benefit of
high-dose folic acid, on-going outcome studies with moderate
doses of folate in patients with cardiovascular disease (0.8 to
2.5 mg)26 may not reveal benefit despite lowering homocys-
teine. This may reflect the lower doses of folate used, and this
point should be borne in mind when interpreting the results of
these studies.
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